高级检索
中华心血管病杂志
期刊首页
过刊列表
高级检索
稿件发表
• 指南与共识 •
ENGLISH ABSTRACT
中国血脂管理指南（基层版2024年）
中国血脂管理指南修订联合专家委员会
作者及单位信息
·
DOI： 10.3760/cma.j.cn112148-20240102-00002
Chinese guideline for lipid management (primary care version 2024)
Joint Committee on the Chinese Guidelines for Lipid Management
Wang Zengwu
Li Jianjun
Zhao Shuiping
Gao Runlin
Authors Info & Affiliations
Joint Committee on the Chinese Guidelines for Lipid Management
Wang Zengwu
Department of Prevention and Community Health, National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Science, Beijing 100037, China
Li Jianjun
Cardiometabolic Medicine Center, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing 100037, China
Zhao Shuiping
Department of Cardiology, the Second Xiangya Hospital of Central South University, Changsha 410011, China
Gao Runlin
Coronary Heart Disease Center, Fuwai Hospital, Chinese Academy of Medical Science, Beijing 100037, China
·
DOI： 10.3760/cma.j.cn112148-20240102-00002
14499
3690
0
14
321
79
PDF下载
APP内阅读
摘要

低密度脂蛋白胆固醇（LDL-C）是动脉粥样硬化性心血管疾病（ASCVD）的致病性危险因素。近几十年来，中国人群的血脂异常患病率不断升高，血脂管理刻不容缓，在基层开展血脂规范管理尤为重要。《中国血脂管理指南（基层版2024年）》简明地推荐LDL-C作为血脂干预的首要靶点，以ASCVD危险分层确定其目标值；推荐在生活方式干预的基础上，以中等强度他汀类药物作为起始药物治疗，必要时联用胆固醇吸收抑制剂和（或）前蛋白转化酶枯草溶菌素9抑制剂的达标策略；并就常见特殊人群的血脂管理策略进行了推荐。该指南旨在为基层医师开展血脂管理提供指导，全面提升基层医师的血脂管理水平，推进ASCVD的一级和二级预防工作。

动脉粥样硬化;心血管疾病;血脂管理;低密度脂蛋白胆固醇;基层
引用本文

中国血脂管理指南修订联合专家委员会. 中国血脂管理指南（基层版2024年）[J]. 中华心血管病杂志,2024,52(04)：330-337.

DOI:10.3760/cma.j.cn112148-20240102-00002

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
本文评分
4.33分 [累计6个]

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

以动脉粥样硬化性心血管疾病（atherosclerotic cardiovascular disease，ASCVD）为主的心血管疾病（cardiovascular disease，CVD）是我国城乡居民第一位死亡原因，占死因构成的40%以上 ［ 1 ］ 。近年来，我国ASCVD的负担仍持续增加，防控形势严峻。目前已证实，低密度脂蛋白胆固醇（low-density lipoprotein cholesterol，LDL-C）是ASCVD的致病性危险因素 ［ 2 ］ 。然而，数据显示，近几十年来我国≥18岁人群血脂异常患病率明显升高 ［ 3 ］ ，但其知晓率、治疗率和控制率均处于较低水平。因此，有必要进一步加强血脂管理，做好ASCVD的一级和二级预防。
2023年3月24日，由国家心血管病专家委员会联合中华医学会心血管病学分会、内分泌学分会、糖尿病学分会、检验医学分会及中国卒中学会发布了《中国血脂管理指南（2023年）》 ［ 4 ］ 。为便于基层医师更好地开展血脂管理，在该指南基础上制定了《中国血脂管理指南（基层版2024年）》。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
国家心血管病中心. 中国心血管健康与疾病报告2021[M]. 北京:科学出版社, 2022.
返回引文位置
[2]
Ference BA , Ginsberg HN , Graham I ,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J, 2017,38(32):2459-2472. DOI: 10.1093/eurheartj/ehx144 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
国家卫生健康委员会疾病预防控制局. 中国居民营养与慢性病状况报告2015[M]. 北京:人民卫生出版社, 2015.
返回引文位置
[4]
中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中华心血管病杂志, 2023,51(3):221-255. DOI: 10.3760/cma.j.cn112148-20230119-00038 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials[J]. Lancet, 2012,380(9841):581-590. DOI: 10.1016/S0140-6736(12)60367-5 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Cholesterol Treatment Trialists Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174, 000 participants in 27 randomised trials[J]. Lancet, 2015,385(9976):1397-1405. DOI: 10.1016/S0140-6736(14)61368-4 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Yusuf S , Bosch J , Dagenais G ,et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease[J]. N Engl J Med, 2016,374(21):2021-2031. DOI: 10.1056/NEJMoa1600176 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Ridker PM , Mora S , Rose L . Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents[J]. Eur Heart J, 2016,37(17):1373-1379. DOI: 10.1093/eurheartj/ehw046 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Bangalore S , Fayyad R , Kastelein JJ ,et al. 2013 cholesterol guidelines revisited: percent LDL cholesterol reduction or attained LDL cholesterol level or both for prognosis?[J]. Am J Med, 2016,129(4):384-391. DOI: 10.1016/j.amjmed.2015.10.024 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Schwartz GG , Steg PG , Szarek M ,et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med, 2018,379(22):2097-2107. DOI: 10.1056/NEJMoa1801174 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Zhong VW , Van Horn L , Cornelis MC ,et al. Associations of dietary cholesterol or egg consumption with incident cardiovascular disease and mortality[J]. JAMA, 2019,321(11):1081-1095. DOI: 10.1001/jama.2019.1572 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Ginsberg HN , Karmally W , Siddiqui M ,et al. A dose-response study of the effects of dietary cholesterol on fasting and postprandial lipid and lipoprotein metabolism in healthy young men[J]. Arterioscler Thromb, 1994,14(4):576-586. DOI: 10.1161/01.atv.14.4.576 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Ginsberg HN , Karmally W , Siddiqui M ,et al. Increases in dietary cholesterol are associated with modest increases in both LDL and HDL cholesterol in healthy young women[J]. Arterioscler Thromb Vasc Biol, 1995,15(2):169-178. DOI: 10.1161/01.atv.15.2.169 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Mozaffarian D , Micha R , Wallace S . Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials[J]. PLoS Med, 2010,7(3):e1000252. DOI: 10.1371/journal.pmed.1000252 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Kim BK , Hong SJ , Lee YJ ,et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial[J]. Lancet, 2022,400(10349):380-390. DOI: 10.1016/S0140-6736(22)00916-3 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Christian JB , Arondekar B , Buysman EK ,et al. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dl in patients with severe hypertriglyceridemia[J]. J Clin Lipidol, 2012,6(5):450-461. DOI: 10.1016/j.jacl.2012.08.007 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Bhatt DL , Steg PG , Miller M ,et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia[J]. N Engl J Med, 2019,380(1):11-22. DOI: 10.1056/NEJMoa1812792 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Yokoyama M , Origasa H , Matsuzaki M ,et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis[J]. Lancet, 2007,369(9567):1090-1098. DOI: 10.1016/S0140-6736(07)60527-3 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Keech A , Simes RJ , Barter P ,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial[J]. Lancet, 2005,366(9500):1849-1861. DOI: 10.1016/S0140-6736(05)67667-2 .
返回引文位置Google Scholar
百度学术
万方数据
[20]
ACCORD Study Group . Effects of combination lipid therapy in type 2 diabetes mellitus[J]. N Engl J Med, 2010,362(17):1563-1574. DOI: 10.1056/NEJMoa1001282 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
Cannon CP , Blazing MA , Giugliano RP ,et al. Ezetimibe added to statin therapy after acute coronary syndromes[J]. N Engl J Med, 2015,372(25):2387-2397. DOI: 10.1056/NEJMoa1410489 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
Liao J , Wang X , Li Z ,et al. Pharmacokinetic study of oral (14)C-radiolabeled hyzetimibe, a new cholesterol absorption inhibitor[J]. Front Pharmacol, 2021,12:665372. DOI: 10.3389/fphar.2021.665372 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
O′Donoghue ML , Giugliano RP , Wiviott SD ,et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease[J]. Circulation, 2022;146(15):1109-1119. DOI: 10.1161/CIRCULATIONAHA.122.061620 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
Qi L , Liu D , Qu Y ,et al. Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4): a randomized, double-blind, placebo-controlled phase 3 trial[J]. JACC Asia, 2023,3(4):636-645. DOI: 10.1016/j.jacasi.2023.04.011 .
返回引文位置Google Scholar
百度学术
万方数据
[25]
Fitzgerald K , White S , Borodovsky A ,et al. A highly durable RNAi therapeutic inhibitor of PCSK9[J]. N Engl J Med, 2017,376(1):41-51. DOI: 10.1056/NEJMoa1609243 .
返回引文位置Google Scholar
百度学术
万方数据
[26]
Sabatine MS , Giugliano RP , Keech AC ,et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med, 2017,376(18):1713-1722. DOI: 10.1056/NEJMoa1615664 .
返回引文位置Google Scholar
百度学术
万方数据
[27]
Cholesterol Treatment Trialists Collaborators. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis[J]. Lancet, 2008,371(9607):117-125. DOI: 10.1016/S0140-6736(08)60104-X .
返回引文位置Google Scholar
百度学术
万方数据
[28]
Cholesterol Treatment Trialists Collaboration. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials[J]. Lancet Diabetes Endocrinol, 2016,4(10):829-839. DOI: 10.1016/S2213-8587(16)30156-5 .
返回引文位置Google Scholar
百度学术
万方数据
[29]
Wanner C , Krane V , März W ,et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis[J]. N Engl J Med, 2005,353(3):238-248. DOI: 10.1056/NEJMoa043545 .
返回引文位置Google Scholar
百度学术
万方数据
[30]
Fellström BC , Jardine AG , Schmieder RE ,et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis[J]. N Engl J Med, 2009,360(14):1395-1407. DOI: 10.1056/NEJMoa0810177 .
返回引文位置Google Scholar
百度学术
万方数据
[31]
Mychaleckyj JC , Craven T , Nayak U ,et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants[J]. Diabetes Care, 2012,35(5):1008-1014. DOI: 10.2337/dc11-1811 .
返回引文位置Google Scholar
百度学术
万方数据
[32]
Linz PE , Lovato LC , Byington RP ,et al. Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial[J]. Diabetes Care, 2014,37(3):686-693. DOI: 10.2337/dc13-0790 .
返回引文位置Google Scholar
百度学术
万方数据
[33]
Amarenco P , Labreuche J . Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention[J]. Lancet Neurol, 2009,8(5):453-463. DOI: 10.1016/S1474-4422(09)70058-4 .
返回引文位置Google Scholar
百度学术
万方数据
[34]
Amarenco P , Bogousslavsky J , Callahan A 3rd,et al. High-dose atorvastatin after stroke or transient ischemic attack[J]. N Engl J Med, 2006,355(6):549-559. DOI: 10.1056/NEJMoa061894 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
王增武，中国医学科学院阜外医院 国家心血管病中心社区防治部，北京 100037，Email： mocdef.labiamxofuwgnezgnaw
B
李建军，中国医学科学院阜外医院心血管代谢中心，北京 100037，Email： mocdef.6ab21839nujnaijil
C
赵水平，中南大学湘雅二医院心血管内科，湖南 410011，Email： mocdef.3ab619001psoahz
D
高润霖，中国医学科学院阜外医院冠心病中心，北京 100037，Email： mocdef.dabmticnilnuroag
E
中国血脂管理指南修订联合专家委员会. 中国血脂管理指南（基层版2024年）[J]. 中华心血管病杂志, 2024, 52(4): 330-337. DOI: 10.3760/cma.j.cn112148-20240102-00002.
F
所有作者声明无利益冲突
评论 （0条）
注册
登录
时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
中国咳嗽基层诊疗与管理指南（2024年）
中华医学会 等
中华全科医师杂志 2024,23(08)
中国慢性阻塞性肺疾病基层诊疗与管理指南（2024年）
中华医学会 等
中华全科医师杂志 2024,23(06)
中国血脂管理指南（基层版2024年）
中国血脂管理指南修订联合专家委员会
中国全科医学 2024,27(20)
中国血脂管理指南（2023年）
中国血脂管理指南修订联合专家委员会
中华心血管病杂志 2023,51(03)
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照

你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持：

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大